HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy

AIDS

Volumn 22, Issue 13, 2008, Pages 1583-1588

  Steingrover, Radjin ^a,b   Pogány, Katalyn ^a,c   Fernandez Garcia, Evian ^b   Jurriaans, Suzanne ^a   Brinkman, Kees ^d   Schuitemaker, Hanneke ^e   Miedema, Frank ^f   Lange, Joep Ma ^a,b,c   Prins, Jan M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b International Antiviral Therapy Evaluation Center   (Netherlands)

^c National Antiretroviral Therapy Evaluation Center   (Netherlands)

^d Department of Internal Medicine ^*  (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Highly active antiretroviral therapy; Primary HIV infection; Treatment interruption; Viral rebound

Indexed keywords

NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REBOUND; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT INTERRUPTION; VIREMIA; VIRUS LOAD; BLOOD; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE COURSE; DRUG ADMINISTRATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIRAL LOAD; VIRUS REPLICATION;

EID: 52249094649     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328305bd77     Document Type: Article

References (33)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
2. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-880.
3. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
4. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506.
5. Rosenberg ES, BillingsleyJM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4R T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
6. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
7. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:e36.
8. Girard PM, Schneider V, Dehee A, Mariot P, Jacomet C, Delphin N, et al. Treatment interruption after one year of triple nucleo-side analogue therapy for primary HIV infection. AIDS 2001; 15:275-277.
9. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-733.
10. Steingrover R, Bezemer D, Fernandez Garcia E, Kroon F, de Wolf F, Prins M, et al. Early treatment of primary HIV-1 infection lowers the viral set point [oral abstracts]. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007.
11. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-643.
12. Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16:2049-2054.
13. DesquilbetL, GoujardC, Rouzioux C,SinetM, DeveauC,Chaix ML, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18:2361-2369.
14. Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Disq 2006; 194:734-739.
15. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002; 99:13747-13752.
16. Wit FW, Blanckenberg DH, Brinkman K, PrinsJM, van der Ende ME, Schneider MM, et al. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. AIDS 2005; 19:345-348.
17. Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, LangeJM, et al. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection. Antivir Ther 2003; 8:137-142.
18. Sankatsing SU, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004; 18:1925-1931.
19. Pogany K, van Valkengoed IG, PrinsJM, Nieuwkerk PT, van der Ende I, Kauffmann RH, et al. Effects of active treatment discontinuation in patients with a CD4R T-cell nadir greater than 350cells/mm : 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr 2007; 44:395-400.
20. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-214.
21. Fagard C, Bandelier CY, Ananworanich J, Le Braz M, Gunthard H, Perneger T, et al. Biphasic decline of CD4 cell count during scheduled treatment interruptions. AIDS 2005; 19:439-441.
22. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6:873-879.
23. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4R T cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-1922.
24. Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, et al. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS 2005; 19:1145-1154.
25. Jansen CA, De Cuyper IM, Hooibrink B, van der Bij AK, van Baarle D, Miedema F. Prognostic value of HIV-1 Gag-specific CD4R T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood 2006; 107:1427-1433.
26. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4R T cells. Nature 2002; 417:95-98.
27. Younes SA, Trautmann L, Yassine-Diab B, Kalfayan LH, Kernaleguen AE, Cameron TO, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4R T cells. J Immunol 2007; 178:788-797.
28. Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999; 13:677-683.
29. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4R T cells. Nat Med 2003; 9:727-728.
30. Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999; 180:1827-1832.
31. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-1642.
32. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
33. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 2004; 18:1951-1953.